COMy 2023 | The mechanism of action of modakafusp alfa & the value of this agent in R/R myeloma
In this video, Jonathan Kaufman, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses the mechanism of action of modakafusp alfa, a promising novel agent being explored in relapsed/refractory (R/R) multiple myeloma. Dr Kaufman also shares some results from a Phase I trial investigating this agent in a highly refractory population, which has demonstrated promising results so far. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Modakafusp alfa is a new investigational agent. It’s an anti-CD38 antibody interferon alpha fusion protein, not an antibody-drug conjugate, but a fusion protein. So there’s molecules of an attenuated interferon alpha delivered directly to plasma cells with the anti-CD38 antibody. And we performed a Phase I clinical trial and we’ve identified the right dose and the right dose range and schedule; schedule is given every four weeks...
Modakafusp alfa is a new investigational agent. It’s an anti-CD38 antibody interferon alpha fusion protein, not an antibody-drug conjugate, but a fusion protein. So there’s molecules of an attenuated interferon alpha delivered directly to plasma cells with the anti-CD38 antibody. And we performed a Phase I clinical trial and we’ve identified the right dose and the right dose range and schedule; schedule is given every four weeks. The range is 1.5mg/kg to 3mg/kg. And what this showed in a highly refractory patient population, median seven prior lines of therapy, that the response rate is 43%. And what we also showed in this study was that if you take patients who had not been BCMA exposed, the response rate in this subpopulation was 60%. From a toxicity perspective, the major toxicities are hematologic, thrombocytopenia and neutropenia. But we’re really excited about this medication. It’s a new mechanism of action and amplifies the immune system of myeloma patients and has responses in late lines of therapy, both patients who have had BCMA prior therapy and not.
Read more...
Disclosures
AbbVie, Incyte: Consultant
